BIIB vs WYY · P/E 21, rev $9.89B vs rev $78.6M
Biogen Inc (BIIB) versus Widepoint C (WYY) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Widepoint C (WYY) is a information technology services company listed on AMEX.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported WYY revenue for 2026-06-30 was $78.6M. Net income was $143.4K. Revenue was up 93.7% from 2026-03-31 to 2026-06-30. WYY currently screens at market cap $129.3M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. WYY currently screens at market cap $129.3M.
Not investment advice. Open the BIIB and WYY stock pages for the full models.
Not investment advice.